NysnoBio Partner, Rune Labs, Announces FDA Clearance for StrivePD App
San Francisco | August 23, 2022 – NysnoBio partner, Rune Labs, has secured FDA clearance for Parkinson's Disease (PD) monitoring through its StrivePD ecosystem for smartwatches. With this clearance, the app enables precision clinical care and trial participation for tens of thousands of PD patients who already use these devices in their daily lives. Additionally, the StrivePD app makes it easy for people with PD to track and log their symptoms, enabling more control over their care.
What this means for NysnoBio: This FDA-cleared monitoring will allow NysnoBio to identify specific patient characteristics for our genetic Parkin patients that can be used to design the most effective clinical trials, from patient enrollment to clinical readouts. We look forward to working with Rune Labs as we move our therapies to the clinic, and ultimately to patients.
Says Brian Pepin, Founder and CEO of Rune Labs:
"As we have seen in oncology, the introduction of large quantities of real-world data has the power to transform drug development and fundamentally change disease prognosis. This clearance is a major step towards building a similar paradigm in neurology."
Says Jennifer A. Johnston, PhD, Founder and CEO of NysnoBio:
"This approval is a landmark in improving patient outcomes and advancing new therapies for PD that can alter the course of the disease. This innovation ensures that the right patients are enrolled in specific clinical trials, and that more robust data is generated to support regulatory approval. All of this means getting new innovative medicines to patients faster."
Read the full press release from Rune Labs here.
Contact NysnoBio to get involved or learn more:
info@nysnobio.com
